Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG)

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1602-1605

  Malogolowkin, Marcio H ^a   Krailo, Mark ^b   Marina, Neyssa ^c   Olson, Thomas ^d   Frazier, A Lindsay ^e  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cyclophosphamide; Germ cell tumors; Maximum tolerated doses

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DRUG DOSE ESCALATION; EVENT FREE SURVIVAL; FEMALE; GERM CELL TUMOR; HUMAN; INFANT; MALE; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEWBORN; PILOT STUDY; POST TREATMENT SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SECOND LOOK SURGERY; TREATMENT DURATION; TREATMENT RESPONSE;

CYCLOPHOSPHAMIDE; GERM CELL TUMORS; MAXIMUM TOLERATED DOSES;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PILOT PROJECTS; SURVIVAL RATE;

EID: 84881502073     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24601     Document Type: Article

References (10)

1. Cushing B, Giller R, Cullen JW. et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children with high-risk malignant germ cell tumors: A Pediatric Intergroup Study-(POG 9049/CCG 8882). J Clin Oncol 2004; 22:2691-2700.
2. Marina N, Chang KW, Malogolowkin M. et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ cell tumors. A Children's Oncology Group Study. Cancer 2005; 104:841-847.
3. Kong N, Heller C, Heller G. Chemotherapy dose intensification correlates strongly with response, median survival and progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9:1050.
4. Anderson JR, Coccia PF. Is more better? Dose intensification in neuroblastoma. J Clin Oncol 1991; 9:902.
5. Goldberg MA, Antin JH, Guinan EC. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986; 68:1114-1118.
6. Stillwell TJ, Benson RCJ. Cyclophosphamide-induced hemorrhagic cystitis. Cancer 1988; 61:451-457.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
8. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley & Sons; 1980.
9. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumors among childhood cancer survivors. Br J Cancer 1987; 56:339-347.
10. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998; 16:3016-3020.